Co-transplantation of Mesenchymal Stem Cell Derived Exosomes and Autologous Mitochondria for Patients Candidate for CABG Surgery
Myocardial Infarction, Myocardial Ischemia, Myocardial Stunning
About this trial
This is an interventional treatment trial for Myocardial Infarction
Eligibility Criteria
Inclusion Criteria: • Patients who are candidate for CABG due to CAD±MR History of Q-wave MI, less than one month Age: 35-80 LVEF <=25% (by any imaging modality: echocardiography/SPECT/LV angiography and Cardiac MRI) Viability study as evidenced by low-dose dobutamine stress echocardiogram and/or or thallium redistribution nuclear study (at least four viable segments). Exclusion Criteria: Severe co-morbidities (e.g., renal failure, liver failure, etc.) Inability to provide informed consent Cerebral Damage
Sites / Locations
- Tehran University of Medical SciencesRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
exosome therapy
mitochondria therapy
co-transplantation of mitochondria and exosome therapy
placebo
a) Intracoronary and intra-myocardial injection of exosomes (5 patients) 1 mL of exosomes containing 100 micrograms of exosomes
b) Intracoronary and intra-myocardial injection of mitochondria (5 patients) 1 mL of exosomes containing 10 million mitochondria
c) co-transplantation Intracoronary and intra-myocardial injection of exosomes and mitochondria (5 patients) 1 mL of exosomes containing 100 micrograms of exosomes 1 mL of exosomes containing 10 million mitochondria
1 mL of placebo solution